26 May 2013
Keywords: glaxo, wellcome, gains, relenza, approval, usa, launch
Article | 28 July 1999
Glaxo Wellcome says that it has received approval from the US Food andDrug Administration for its neuraminidase inhibitor Relenza (zanamivir).
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 July 1999
27 July 1999
24 May 2013
© 2013 thepharmaletter.com